Burlington, Massachusetts, October 12, 2018 — MilliporeSigma today announced that it has won two CPhI Pharma Awards for innovative products for the pharmaceutical industry. The awards were announced at CPhI’s award gala in Madrid, Spain. CPhI (Convention on Pharmaceutical Ingredients) Pharma is a global organization that connects people within the pharmaceutical industry and celebrates thinkers, creators and companies breaking new ground.
“At MilliporeSigma, we provide innovations that help our customers advance science and accelerate access to better health for people everywhere,” said Andrew Bulpin, head of Process Solutions at MilliporeSigma. “We are pleased that CPhI has recognized our commitment to drive the industry forward and empower researchers and scientists with products that improve drug development quality and efficiency.”
The company received the following awards:
Parteck® MXP Excipient won for “Excellence in Excipients.” Parteck® MXP excipient is a new polyvinyl alcohol excipient for the formulation of stable amorphous solid dispersions by hot melt extrusion, providing enhanced solubility of active pharmaceutical ingredients (APIs) and stable, high drug loads. The new excipient is applicable for a variety of final formulations with different release kinetics and offers the formulator flexibility in designing a drug product that fits the respective API and desired therapeutic effect.
MilliporeSigma’s modified amino acids won for “Excellence in Bioprocessing and Manufacturing.” The modified amino acids Phospho-Tyrosine disodium salt and Sulfo-Cysteine sodium salt are components for biomanufacturing and mAb processes, designed to simplify fed batch processes in applying a single-feed strategy.
CPhI Pharma is a global organization that connects people within the pharmaceutical sector and creates opportunities for pharma companies to develop new business, meet customers, launch new products, promote brands and expand into new markets. The CPhI Pharma Awards celebrate thinkers and creators breaking new ground in the industry and advocate companies that are committed to driving the industry forward.
About the Life Science Business of Merck KGaA, Darmstadt, Germany
The Life Science business of Merck KGaA, Darmstadt, Germany, which operates as MilliporeSigma in the U.S. and Canada, has some 22,000 employees and 59 manufacturing sites worldwide, with a portfolio of more than 300,000 products focused on scientific discovery, biomanufacturing, and testing services. Matthias Heinzel is the CEO of MilliporeSigma and a member of the Executive Board of Merck KGaA, Darmstadt, Germany.
Merck KGaA, Darmstadt, Germany, a leading science and technology company, operates across healthcare, life science, and electronics. Around 58,000 employees work to make a positive difference to millions of people’s lives every day by creating more joyful and sustainable ways to live. From advancing gene-editing technologies and discovering unique ways to treat the most challenging diseases to enabling the intelligence of devices – the company is everywhere. In 2020, Merck KGaA, Darmstadt, Germany generated sales of € 17.5 billion in 66 countries.
The company holds the global rights to the name and trademark “Merck” internationally. The only exceptions are the United States and Canada, where the business sectors of Merck KGaA, Darmstadt, Germany operate as EMD Serono in healthcare, MilliporeSigma in life science, and EMD Electronics. Since its founding in 1668, scientific exploration and responsible entrepreneurship have been key to the company’s technological and scientific advances. To this day, the founding family remains the majority owner of the publicly listed company. For more information about Merck, KGaA, Darmstadt, Germany, visit www.emdgroup.com.